Fractyl Health announced today that six-month data from a study of its diabetes reversal tech demonstrated improvements in glucose control. Interim data came from the human clinical experience in Fractyl's Revita-T2Di long-term, open-label cohort. … [Read More...] about Fractyl Health ‘encouraged’ by results from diabetes reversal study
Main Content
Sponsored Content
Noble Leads with its User-Centered Design Strategy
By Tim McLeroy, Executive Director of Marketing and Patient Services, Noble International At Noble, the patient journey drives everything we do. Our patient-centered approach pushes us to fully … [Read More...] about Noble Leads with its User-Centered Design Strategy
Featured Posts
Tidepool Loop automated insulin delivery system wins FDA clearance
Tidepool announced recently that the FDA cleared its Tidepool Loop, a “do-it-yourself,” (DIY) automated insulin delivery (AID) system. Palo Alto, California-based Tidepool is a non-profit diabetes data management group. It created the hybrid, … [Read More...] about Tidepool Loop automated insulin delivery system wins FDA clearance
Know Labs inks partnerships to accelerate progress toward FDA clearance for glucose monitor
Know Labs (NYSE:KNW) announced that it entered into a series of strategic partnerships as it looks to move toward a major regulatory nod. Seattle-based Know Labs develops the Bio-RFID technology. It uses spectroscopy to direct electromagnetic … [Read More...] about Know Labs inks partnerships to accelerate progress toward FDA clearance for glucose monitor
Vero Biotech wins FDA approval for inhaled nitric oxide delivery with anesthesia in the OR
Vero Biotech announced that the FDA approved its second-generation Genosyl system for use with rebreathing anesthesia in the operating room setting. Atlanta-based Vero Biotech designed Genosyl for inhaled nitric oxide (iNO) delivery. This approval … [Read More...] about Vero Biotech wins FDA approval for inhaled nitric oxide delivery with anesthesia in the OR
Boston Scientific hit with $42M verdict in drug-eluting stents IP case
Boston Scientific (NYSE:BSX) must pay $42 million in unpaid royalties to TissueGen and the University of Texas, a federal jury in Delaware has ruled. The jury verdict yesterday came after the finding that Boston Scientific's Synergy BP … [Read More...] about Boston Scientific hit with $42M verdict in drug-eluting stents IP case
How Embecta started strong and what’s ahead for the BD diabetes spinoff
Ten months after spinning off from BD, Embecta CEO Dev Kurdikar lays out what the future holds for the diabetes technology company. When Embecta became a standalone company in April 2022, CFO Jake Elguicze said he felt it was "uniquely … [Read More...] about How Embecta started strong and what’s ahead for the BD diabetes spinoff
Owen Mumford wins Pharmapack award for UniSafe auto-injector
Pharmapack Europe today announced that Owen Mumford Pharmaceutical Services received one of its 2023 Pharmapack Awards. The company received recognition in the "Drug Delivery Innovation" category for its UniSafe reusable, connected … [Read More...] about Owen Mumford wins Pharmapack award for UniSafe auto-injector
Phillips-Medisize unveils new disposable injector pen
Phillips-Medisize, a Molex company, announced today that it expanded its product portfolio with a new disposable pen injector. Hudson, Wisconsin-based Phillips-Medisize designed the new injector for high-volume manufacturing. It intends to offer … [Read More...] about Phillips-Medisize unveils new disposable injector pen
Fractyl Health ‘encouraged’ by results from diabetes reversal study
Fractyl Health announced today that six-month data from a study of its diabetes reversal tech demonstrated improvements in glucose control. Interim data came from the human clinical experience in Fractyl's Revita-T2Di long-term, open-label cohort. … [Read More...] about Fractyl Health ‘encouraged’ by results from diabetes reversal study
Study backs digital diabetes program from Vida Health
Vida Health announced that a study of its digital health diabetes management program demonstrated improvements in multiple metrics. San Francisco-based Vida Health published an article in JMIR Formative Research. Results from 1,128 participants … [Read More...] about Study backs digital diabetes program from Vida Health
Aptar Pharma launches metal-free nasal spray pump
Aptar Pharma announced today that it launched its first metal-free, multidose nasal spray pump, called the APF Futurity. Crystal Lake, Illinois-based Aptar developed APF Futurity to deliver nasal saline and other comparable over-the-counter (OTC) … [Read More...] about Aptar Pharma launches metal-free nasal spray pump
In case you missed it
- Glucose monitor maker Know Labs names new CEO, makes other executive changes
- Nemaura Medical garners U.S.-based purchase order for glucose sensors
- Embecta opens new global headquarters in New Jersey
- The year ahead in diabetes care: what to expect in 2023
- Eli Lilly to invest $450M in North Carolina diabetes treatment manufacturing facility
- Tandem Diabetes Care completes acquisition of insulin pump maker AMF Medical
- Canadian university set for Phase 2 human trials of inhaled COVID-19 vaccine
- Eitan Medical opens new manufacturing facility for wearable drug delivery platform
- How Dexcom aims to extend its mission beyond diabetes
- Oramed may discontinue oral insulin activity for type 2 diabetes after trial misses endpoints
- Diabeloop, EOFlow partner on wearable automated insulin delivery in Europe
- This AI-based smartphone app helps diabetes patients manage blood sugar
- Vero Biotech raises $30M for tankless nitric oxide delivery system
- Tandem Diabetes Care expects double-digit revenue growth in 2023
- MedAlliance picks up FDA IDE nod for drug-eluting balloon
Clinical Trials
Fractyl Health ‘encouraged’ by results from diabetes reversal study
Fractyl Health announced today that six-month data from a study of its diabetes reversal tech demonstrated improvements in glucose control. Interim data came from the human clinical experience in Fractyl’s Revita-T2Di long-term, open-label cohort. Revita, a procedure that remodels the duodenal lining via hydrothermal ablation, has FDA breakthrough device designation. The FDA approved an investigational […]
Study backs digital diabetes program from Vida Health
Vida Health announced that a study of its digital health diabetes management program demonstrated improvements in multiple metrics. San Francisco-based Vida Health published an article in JMIR Formative Research. Results from 1,128 participants demonstrated dramatic improvements in glycemic control. It also highlighted an important relationship between the improved management of depression and diabetes. Participants enrolled in […]
Canadian university set for Phase 2 human trials of inhaled COVID-19 vaccine
Researchers at McMaster University in Canada announced that they received $8.2 million from the Canadian Institutes of Health Research (CIHR). Fiona Smaill picked up $8.2 million to advance an inhaled COVID-19 vaccine through to Phase 2 human trials. The trials will evaluate the safety and immunogenicity of the next-generation vaccine delivered by inhaled aerosol. Her […]
Oramed may discontinue oral insulin activity for type 2 diabetes after trial misses endpoints
Oramed Pharmaceuticals (Nasdaq:ORMP) announced that top-line Phase 3 trial results for its oral insulin candidate missed its endpoints. The Phase 3, randomized, double-blind, placebo-controlled trial compared the efficacy of ORMD-0801 to placebo. It evaluated patients with type 2 diabetes at 26 weeks. ORA-D-013-1 enrolled 710 patients with T2D and inadequate glycemic control. Those patients were […]
This AI-based smartphone app helps diabetes patients manage blood sugar
Oregon Health & Science University (OHSU) combined AI and diabetes experts to develop a smartphone app to help manage blood sugar levels. OHSU biomedical engineer Peter Jacobs and OHSU endocrinologist Dr. Leah Wilson lead this project. They plan to organize a randomized clinical trial to evaluate an enhanced app used in concert with diabetes education […]
